Advance new therapies
Stay human

BiomimX unlocks in vitro models reflecting human complexity, towards the design of effective treatments tailored for patients.

Beating Organs-on-Chip are the next generation of pre-clinical models: human, dynamic, 3D.

BiomimX unlocks in vitro models reflecting human complexity, towards the design of effective treatments tailored for patients.
Beating Organs-on-Chip are the next generation of pre-clinical models:
human, dynamic, 3D.

Advance new therapies
Stay human

Discover the therapies of tomorrow
by catching human data today

Every tissue in the body is subjected to motion.

Our Beating Organs-on-Chip finally bring this motion into the 3D native microenvironment, offering clinically relevant human in vitro setups.

Every tissue in the body is subjected to motion.

Our Beating Organs-on-Chip finally bring this motion into the 3D native microenvironment, offering clinically relevant human in vitro setups.

Discover our Services

Test Your Compounds in Human Relevant in vitro Models

Boost Your Pipeline

BiomimX provides services to enhance every step of your pipeline by relying on native-like data from uBeat®-powered models.

Partner with us and leverage on BiomimX®’s expertise and strong scientific know-how, to get your product profiled.

Get inspired by our Applications

Safety - Toxicology

Predict safety and toxicity of therapeutic candidates in human models.

Efficacy in Diseases

Predict therapeutic candidates’ efficacy in human models of diseases.

Advanced Therapies

Predict the toxicity and efficacy of gene, antibody and cell therapeutics in human models.

Microbiome interaction

Elucidate gastrointestinal microbiome interaction at patient specific level.

Discover our Products

Develop Your in vitro Physiological & Pathological Models

uBeat® Platform & uBoX Pro

The uBeat® Setup supports the culture of 3D microtissue models within the  uBeat® Platform.

The patented uBeat® Technology allows to provide a controlled mechanical stimulation to the microtissues through the uBoX Pro.

The mechanical stimulation will drive the model development, mimicking the native human tissues.

Get inspired by our uBeat®-powered models

uHeart

homepage_ubeat_tissue
uHeartSymbol_nowaves_website

A functional beating human Heart-on-a-Chip with real time electrical activity recording functionality.

uKnee

uknee
uKneeSymbol_nowaves_website

The first in vitro miniaturized models of human healthy and osteoarthritic Cartilage-on-Chip.

uGut

uGut_webpage_cover
uGut_Symbol_nowaves_Website

A human model of the gastrointestinal tract, with intestinal epithelium and endothelium.

uScar

uScar_webpage_cover
uScar_nowaves_website

A miniaturized human model recapitulating the key traits of cardiac fibrosis.

Learn more about our
Biological Models and Scientific Expertise

From our high-ranked publications on peer-reviewed journals

An Advanced Mechanically Active Osteoarthritis-on-Chip Model to Test Injectable Therapeutic Formulations: The SYN321 Case Study

Advanced Healthcare Materials
Sep 2024

2_adv_fibrosis publication1

In Vitro Mechanical Stimulation to Reproduce the Pathological Hallmarks of Human Cardiac Fibrosis on a Beating Chip and Predict The Efficacy of Drugs and Advanced Therapies

Advanced Healthcare Materials
Nov 2023

3_adv_liv heart1

LivHeart: A Multi Organ-on-Chip Platform to Study Off-Target Cardiotoxicity of Drugs Upon Liver Metabolism

Advanced Materials Technologies
Jan 2023

4_tox_qt alterations1

Predicting human cardiac QT alterations and pro-arrhythmic effects of compounds with a 3D beating heart-on-chip platform

Toxicological Sciences
Oct 2022

Read all Publications

Meet us

December 2-5 2024

Join our CEO Paola Occhetta and our Commercial Science Leader at the Biofit 2024, to be held in Lille, France.

stay tuned BiomimX

Latest News

Biofit 2024
📢 Meet us at Biofit 2024 next week!

As member of Mabdesign, BiomimX will attend Biofit that will take place from the 2nd to the 5th December in Lille, France.

You will have the opportunity to meet our CEO, Dr. Paola Occhetta and our Commercial Science Leader, Dr. Erika Ferrari to discover how our uBeat®-Powered in vitro models are revolutionizing pre-clinical research and boost pharmaceutical pipelines, recapitulating the key physio-pathological features of human organs.

Also, don’t miss our Pitch that will be presented on the 4th of December!

Event website
Queen Mary University of London Facilities

We are incredibly proud to announce that Queen Mary University of London recently acquired different in vitro model facilities for educational purposes and BiomimX uBeat® setup, is one of them!

These facilities have been funded through a mixture of commercial partnerships, internal funding, research project grants and a large infrastructure grant from the NC3Rs and BBSRC. The facilities are integrated with category II cell culture, advanced microscopy and molecular biology and biochemistry facilities.

Learn more
Innovation Radar Prize 2024
🎉 Exciting News: BiomimX is a Finalist for the Innovation Radar Prize 2024! 🎉

Join us for the grand presentation at The Europas Awards on the afternoon of November 11th at La Distillerie in Lisbon! 🏆 Every finalist will deliver a 3-minute pitch, and we are proud to be represented by our co-founders, CEO Paola Occhetta and CTO Marco Rasponi. Our CEO will take the stage to deliver BiomimX’s 3-minute pitch!

Register for the Awards Presentation
BiomimX & Synartro
New Publication
📢 Publication Alert!!

BiomimX is excited to announce that the results of our collaboration with Synartro have just been published on Advanced Healthcare Materials.
The collaboration was born from the need to test the efficacy of SYN321, a pioneering Intra-Articular (IA) drug candidate for Osteoarthritis (OA) therapy, on an in vitro model able to recapitulate the key pathological features of OA. We brought our technological and biological expertise into this collaboration by testing the effect of SYN321 on our model of OA, developed in a novel platform, the uBeat® MultiCompress, tailored for the injection of viscous therapeutics.
The findings of this research, have also been accepted by Swedish regulatory authorities as part of an Investigational New Drug (IND) application, clearing the way for phases 1 and 2a of clinical trials.

Publication